After therapy in patients with a short-length history, the gal-3 level decreased, losing its statistically higher level comparing to the controls (p < 0.05), while in patients with longer-lasting psoriasis the gal-3 level had an upward trend and stayed still significantly elevated in comparison to the control group (p < 0.01) (Figure 3). The gene discussed is LGALS3; the disease is psoriasis.